Ascentage Pharma Group International vs Protalix Biotherapeutics
Ascentage Pharma Group International is the larger business, with $79.9m of revenue in fiscal 2025 against $52.7m for Protalix Biotherapeutics (1.5 times as much). Protalix Biotherapeutics grew faster (-1.2% against -41.4%). Protalix Biotherapeutics kept more of each dollar of sales as profit: a net margin of -12.5% against -216.5%. Protalix Biotherapeutics carries less debt relative to equity (0.0% against 150.1%).
| Latest fiscal year | Ascentage Pharma Group InternationalAAPG, 2025 | Protalix BiotherapeuticsPLX, 2025 |
|---|---|---|
| Revenue | $79.9m | $52.7m |
| Revenue growth | -41.4% | -1.2% |
| Net income | −$173m | −$6.6m |
| Operating margin | — | -10.4% |
| Net margin | -216.5% | -12.5% |
| Return on equity | -153.3% | -14.4% |
| Free cash flow | −$167m | −$13.6m |
| Cash | $171m | $14.7m |
| Total debt | $284m | $0 |
| Debt to equity | 150.1% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $1.3m | — |
| Employees | — | 226 |
| Market value | $1.26bn | $203m |
| Price vs our value range | — | — |
| Moat score | — | 27 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 1 sales |